November 20, 2025.
Vancouver, British Columbia — November 19, 2025 — Leads & Copy — SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) announced it has signed a non-binding letter of intent (LOI) with GlucaPharm Inc. for a potential share exchange transaction.
Under the LOI, SureNano will conduct legal, technical, and financial due diligence on GlucaPharm. If SureNano chooses to proceed after the due diligence, the companies will negotiate a definitive binding agreement.
The LOI includes binding terms such as mutual confidentiality, due diligence access rights, each party bearing its own expenses, and mutual exclusivity of negotiations. The non-binding terms relate to the substantive terms of the proposed share exchange.
GlucaPharm, a private BC Corporation, holds exclusive rights to develop Syracuse University’s GEP-44 GLP-1 pharmaceutical patent protected compound discovery and technology. GEP-44 is a novel compound that addresses diabetes and weight loss, similar to current in-market GLP-1s such as Ozempic, but targeting no-needle administration method and superior tolerability, including reduced side effects most experienced by leading in-market drugs such as nausea and gastrointestinal issues. GEP-44 is a triple antagonist with strong preclinical results, patents filed, academic validation and market exploration underway, poised to transform the treatment of obesity and diabetes worldwide.
The proposed transaction is expected to be structured as a share exchange, where SureNano would acquire 100% of GlucaPharm’s outstanding common shares by issuing SureNano shares to GlucaPharm shareholders. Following the closing, it is expected that GlucaPharm shareholders will collectively own under 20% of the issued and outstanding SureNano Shares.
Completion of the proposed transaction is subject to conditions including due diligence, negotiation and execution of a definitive agreement, and receipt of required regulatory and third-party approvals. There is no guarantee that the transaction will be completed.
Upon execution of a definitive agreement, SureNano will issue a subsequent news release with details of the agreement and any additional terms.
Finder’s fees may be payable in connection with the proposed transaction, in accordance with Canadian Securities Exchange policies.
SureNano also announced on November 5, 2025, its intention to complete a private placement for proceeds of up to $1,250,000. The private placement will consist of the sale of up to 10,000,000 units at $0.125 per unit. Each unit will include one common share and one common share purchase warrant. Each warrant allows the holder to acquire one common share at $0.35 per share for 24 months from the issuance date.
The warrants will be subject to an acceleration provision. If SureNano’s shares trade on the CSE at a closing price of $0.50 or greater per share for ten consecutive trading days after a four-month holding period, SureNano can accelerate the warrant expiry to 30 days after notice is given to warrant holders. Proceeds from the private placement will be used for operating expenses, working capital, exploring new markets for its SureNano™ surfactant, and investigating complementary industries including but not limited to GlucaPharm.
SureNano Science Ltd. sells and distributes the SureNano™ surfactant, a ready-to-mix food-grade compound that serves as a base for high-performance nanoemulsions, enhancing bioavailability, clarity, and taste. SureNano has an exclusive license to distribute the SureNano™ surfactant in Canada, Oklahoma, USA, and Colorado, USA.
Charles MaLette, CEO, President, Director & Secretary
604-428-5171
info@surenano.com
Source: SureNano Science Ltd.
